Available therapies for patients with lung cancer are associated with a number of significant toxicities that must be effectively managed by oncologists.
Available therapies for patients with lung cancer are associated with a number of significant toxicities that must be effectively managed by oncologists. These toxicities adversely affect quality of life in such patients, providing further impetus for more effective and more tolerable treatment options for patients with lung cancer.
Selective delivery of anticancer agents remains a key obstacle in implementing effective therapies for both primary and secondary, or metastatic, cancers. Recent data demonstrate that saposin C-dioleoylphosphatidylserine (SapC-DOPS) induces tumor apoptosis and significantly inhibits tumor growth in preclinical models and may be a promising treatment for lung cancer.SapC-DOPS is a biotherapeutic agent composed of a lysosomal protein (saposin C) and a phospholipid (dioleoylphosphatidylserine), which is incorporated into nanovesicles that selectively target and induce cancer cell death. These actions are a consequence of the affinity of SapC-DOPS for phosphatidylserine, an acidic phospholipid abundantly present in the membrane surface of a variety of tumor cells and tumor-associated vasculature.1,2
Viability assays showed that SapC-DOPS cytotoxicity was positively correlated with cell surface phosphatidylserine levels. These specific actions spare normal cells and tissues, which suggests the potential for reducing adverse effects associated with lung cancer treatment.
The binding of SapC-DOPS to phosphatidylserine is favored at acidic pH, which characterizes the milieu of many solid tumors.1Results of this study support SapC-DOPS binding to lung cancer cells was more pronounced at low pH.Results from several studies suggest that SapC-DOPS nanovesicles may be a promising treatment option for lung cancer. In addition to lung cancer, other studies indicate that SapC-DOPS has shown selective cytotoxic activity in pancreatic cancer3,4, skin cancer5, and primary and metastatic brain tumors6, while conferring a significant survival advantage in a preclinical model of breast cancer metastasis to the brain.2,6Data suggest that systemically delivered SapC-DOPS nanovesicles are well tolerated and do not induce hepatotoxicity or manifest adverse effects.7
The agent warrants further clinical study, according to its inventor, Xiaoyang Qi, PhD, associate professor of medicine, division of hematology-oncology, department of internal medicine, University of Cincinnati College of Medicine, Ohio.
Repotrectinib Elicits an Intracranial Response in ROS1+ Advanced NSCLC
March 25th 2024During a Case-Based Roundtable® event, Christine, Bestvina, MD, discussed the intracranial responses to repotrectinib for patients with ROS1-psotive non–small cell lung cancer in the first article of a 2-part series.
Read More
George Discusses Potency of VEGF TKIs in Advanced Renal Cell Carcinoma
March 22nd 2024During a Case-Based Roundtable® event, Saby George, MD, discussed the case of a patient with clear cell renal cell carcinoma who progressed after left nephrectomy followed by treatment with axitinib plus pembrolizumab at recurrence.
Read More
Lachowiez Considers the Use of Tagraxofusp in BPDCN as Bridge to SCT With Peers
March 21st 2024During a Targeted Oncology™ Case-Based Roundtable™ event, Curtis Lachowiez, MD, discussed targeted therapy for blastic plasmacytoid dendritic cell neoplasm and its role in patients who could receive allogeneic stem cell transplant.
Read More